or Try an Advanced Search...

    Technical Analysis for ASND - Ascendis Pharma A/S

    Grade Last Price % Change Price Change
    C 133.98 -1.76% -2.40
    ASND closed down 1.76 percent on Monday, July 1, 2024, on 55 percent of normal volume. It was able to find support at its 50 day moving average. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Up
    Historical ASND trend table...
    Date Alert Name Type % Chg
    50 DMA Support Bullish 0.00%
    MACD Bullish Centerline Cross Bullish 0.00%
    Stochastic Reached Overbought Strength 0.00%
    Outside Day Range Expansion 0.00%
    Overbought Stochastic Strength 0.00%
    Crossed Above 50 DMA Bullish -1.05%
    Fell Below 50 DMA Bearish 1.00%
    20 DMA Support Bullish 1.00%
    Crossed Above 20 DMA Bullish -1.33%
    Crossed Above 50 DMA Bullish -1.33%
    Older End-of-Day Signals for ASND ...

       Recent Intraday Alerts

    Alert Time
    Down 3% about 6 hours ago
    Fell Below 50 DMA about 6 hours ago
    50 DMA Support about 7 hours ago
    Outside Day about 7 hours ago
    Fell Below Previous Day's Low about 7 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    ASND Chart by TradingView
    Basic chart:

    Profile

    Ascendis Pharma A/S Description

    Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone that has completed Phase II clinical trials in adults to treat growth hormone deficiency (GHD) and other indications, as well as in Phase II studies in children for treating GHD; and TransCon Treprostinil for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. The company is also developing TransCon Insulin for the treatment of diabetes; and TransCon Ranibizumab, a compound to support ranibizumab injection. It has strategic collaborations with Sanofi, Genentech, and United Therapeutics Corporation. The company was founded in 2006 and is headquartered in Hellerup, Denmark.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Life Sciences Disease Diabetes Hypertension Insulin Hormones Breakthrough Therapy Pulmonary Arterial Hypertension Peptide Hormones Drug Therapies Growth Hormone Treatment Of Diabetes Growth Hormone Deficiency Recombinant Proteins Growth Hormone Therapy Prodrug Treprostinil

    Is ASND a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 24 Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024
    Jun 21 Ascendis Pharma A/S (ASND) Stock Soared on Unexpected Demand
    Jun 4 Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
    Jun 3 Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024
    May 31 If You Invested $100 In This Stock 15 Years Ago, You Would Have $4,100 Today
    May 30 Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024
    May 15 FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months
    May 15 FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing
    May 14 US Equity Markets Close Higher Tuesday as Producer Prices Rise
    May 14 Ascendis Pharma says FDA has delayed TransCon PTH review
    See more ASND news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 161.0
    52 Week Low 85.285
    Average Volume 392,364
    200-Day Moving Average 124.29
    50-Day Moving Average 132.77
    20-Day Moving Average 131.75
    10-Day Moving Average 130.08
    Average True Range 5.29
    RSI (14) 53.05
    ADX 18.99
    +DI 24.99
    -DI 18.64
    Chandelier Exit (Long, 3 ATRs) 127.90
    Chandelier Exit (Short, 3 ATRs) 136.93
    Upper Bollinger Bands 141.52
    Lower Bollinger Band 121.97
    Percent B (%b) 0.61
    BandWidth 14.84
    MACD Line 0.18
    MACD Signal Line -0.80
    MACD Histogram 0.9748
    Fundamentals Value
    Market Cap 7.59 Billion
    Num Shares 56.6 Million
    EPS -9.21
    Price-to-Earnings (P/E) Ratio -14.55
    Price-to-Sales 30.12
    Price-to-Book 14.55
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 142.74
    Resistance 3 (R3) 143.14 140.63 141.28
    Resistance 2 (R2) 140.63 138.40 140.43 140.79
    Resistance 1 (R1) 137.30 137.02 136.05 136.90 140.31
    Pivot Point 134.79 134.79 134.16 134.59 134.79
    Support 1 (S1) 131.46 132.56 130.21 131.06 127.65
    Support 2 (S2) 128.95 131.18 128.75 127.17
    Support 3 (S3) 125.62 128.95 126.68
    Support 4 (S4) 125.22